In this issue:
Immune landscape of human prostate cancer
Long-term functional outcomes after robotic vs retropubic RP
Clinically significant prostate cancers after negative MRI
RP or observation for clinically localised prostate cancer
Multiparametric MRI risk stratification in active surveillance
Response to PARP inhibitor of non-BRCA DNA damage repair gene alterations
Event-free survival as a surrogate for OS
Oral relugolix for ADT
Please login below to download this issue (PDF)